Oral nanomedicines for the treatment of parasitic diseases

Katerina Lalatsa; Dolores Remedios Serrano Lopez; Lindsay Smith; Maria Auxiliadora Dea Ayuela

Oral nanomedicines for the treatment of parasitic diseases

Katerina Lalatsa, Dolores Remedios Serrano Lopez, Lindsay Smith, Maria Auxiliadora Dea Ayuela

Research output: Contribution to conference › Poster › peer-review

113 Downloads (Pure)

Abstract

Self-nanoemulsifying drug delivery systems (SNEDDs) prepared from GRAS excipients (Labrafil M1944CS: Labrasol: Capryol 90: BPQ 30: 59 : 10 : 1% w/w/w/w) enhance the oral bioavailability of a poorly soluble antiparasitic drug, Buparvaquone (BPQ), while maintaining in vitro efficacy against L. infantum promastigotes. BPQ-SNEDDs possess high loading and excellent stability to tropical temperatures while allowing for the complete dissolution of BPQ in simulated gastrointestinal media. We hypothesise that the enhanced solubilisation capacity of BPQ in the GI tract is responsible for the enhanced oral bioavailability. Adsorption of prepared BPQ-SNEDDs on solid carriers (glycol chitosan) and lyophilisation resulted in a solid nanomedicine that can be reconstituted to yield stable BPQ-SNEDDs of nanomolar in vitro activity.

Original language	English
Publication status	Published - 15 Jul 2014
Event	CRS Annual Meeting and Exposition - Chicago Hilton, Chicago, Illinois, United States Duration: 12 Jul 2014 → 16 Jul 2014

Conference

Conference	CRS Annual Meeting and Exposition
Country/Territory	United States
City	Chicago, Illinois
Period	12/07/14 → 16/07/14

Access to Document

ALALATSA CRS 2014 F1 revised ALAccepted author manuscript (Post-print), 355 KB

http://www.controlledreleasesociety.org/meetings/Archives/2014AnnualMeeting/abstracts/pages/2014abstracts.aspx#Micro-andNano-Based

1 Article

Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles
Serrano Lopez, D. R., Lalatsa, K., Dea Ayuela, M. A., Bilbao-Ramos, P. E., Garrett, N. L., Julian, M., Guarro, J., Capilla, J., Paloma Ballesteros, M., Schatzlein, A. G., Bolas, F., Torrado, J. J. & Uchegbu, I. F., 5 Jan 2015, In: Molecular Pharmaceutics.
Research output: Contribution to journal › Article › peer-review

Open Access
File
376 Downloads (Pure)

1 Invited talk

Therapeutic innovations for the treatment of leishmaniasis; Nanomedicines from medicinal plants and poorly soluble drugs
Lalatsa, K. (Speaker)
7 Sept 2018
Activity: Talk or presentation types › Invited talk

File

Cite this

@conference{d45b8de8b1bf464ca67275d9d80db376,

title = "Oral nanomedicines for the treatment of parasitic diseases",

abstract = "Self-nanoemulsifying drug delivery systems (SNEDDs) prepared from GRAS excipients (Labrafil M1944CS: Labrasol: Capryol 90: BPQ 30: 59 : 10 : 1% w/w/w/w) enhance the oral bioavailability of a poorly soluble antiparasitic drug, Buparvaquone (BPQ), while maintaining in vitro efficacy against L. infantum promastigotes. BPQ-SNEDDs possess high loading and excellent stability to tropical temperatures while allowing for the complete dissolution of BPQ in simulated gastrointestinal media. We hypothesise that the enhanced solubilisation capacity of BPQ in the GI tract is responsible for the enhanced oral bioavailability. Adsorption of prepared BPQ-SNEDDs on solid carriers (glycol chitosan) and lyophilisation resulted in a solid nanomedicine that can be reconstituted to yield stable BPQ-SNEDDs of nanomolar in vitro activity. ",

author = "Katerina Lalatsa and {Serrano Lopez}, {Dolores Remedios} and Lindsay Smith and {Dea Ayuela}, {Maria Auxiliadora}",

year = "2014",

month = jul,

day = "15",

language = "English",

note = "CRS Annual Meeting and Exposition ; Conference date: 12-07-2014 Through 16-07-2014",

}

TY - CONF

T1 - Oral nanomedicines for the treatment of parasitic diseases

AU - Lalatsa, Katerina

AU - Serrano Lopez, Dolores Remedios

AU - Smith, Lindsay

AU - Dea Ayuela, Maria Auxiliadora

PY - 2014/7/15

Y1 - 2014/7/15

N2 - Self-nanoemulsifying drug delivery systems (SNEDDs) prepared from GRAS excipients (Labrafil M1944CS: Labrasol: Capryol 90: BPQ 30: 59 : 10 : 1% w/w/w/w) enhance the oral bioavailability of a poorly soluble antiparasitic drug, Buparvaquone (BPQ), while maintaining in vitro efficacy against L. infantum promastigotes. BPQ-SNEDDs possess high loading and excellent stability to tropical temperatures while allowing for the complete dissolution of BPQ in simulated gastrointestinal media. We hypothesise that the enhanced solubilisation capacity of BPQ in the GI tract is responsible for the enhanced oral bioavailability. Adsorption of prepared BPQ-SNEDDs on solid carriers (glycol chitosan) and lyophilisation resulted in a solid nanomedicine that can be reconstituted to yield stable BPQ-SNEDDs of nanomolar in vitro activity.

AB - Self-nanoemulsifying drug delivery systems (SNEDDs) prepared from GRAS excipients (Labrafil M1944CS: Labrasol: Capryol 90: BPQ 30: 59 : 10 : 1% w/w/w/w) enhance the oral bioavailability of a poorly soluble antiparasitic drug, Buparvaquone (BPQ), while maintaining in vitro efficacy against L. infantum promastigotes. BPQ-SNEDDs possess high loading and excellent stability to tropical temperatures while allowing for the complete dissolution of BPQ in simulated gastrointestinal media. We hypothesise that the enhanced solubilisation capacity of BPQ in the GI tract is responsible for the enhanced oral bioavailability. Adsorption of prepared BPQ-SNEDDs on solid carriers (glycol chitosan) and lyophilisation resulted in a solid nanomedicine that can be reconstituted to yield stable BPQ-SNEDDs of nanomolar in vitro activity.

M3 - Poster

T2 - CRS Annual Meeting and Exposition

Y2 - 12 July 2014 through 16 July 2014

ER -

Oral nanomedicines for the treatment of parasitic diseases

Abstract

Conference

Access to Document

Fingerprint

Research output

Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles

Activities

Therapeutic innovations for the treatment of leishmaniasis; Nanomedicines from medicinal plants and poorly soluble drugs

Cite this